Application of alpha7 nicotinic acetylcholine receptor agonists in inflammatory diseases

An overview

Mario B Marrero, Merouane Bencherif, Patrick M. Lippiello, Rudolf Lucas

Research output: Contribution to journalComment/debate

35 Citations (Scopus)

Abstract

Inflammatory disorders are characterized by the influx of immune cells into the vascular wall of veins and/or arteries in response to stimuli such as oxidized-LDL and various pathogens. These factors stimulate the local production of pro-inflammatory cytokines by macrophages and other cells that promote various inflammatory diseases such as atherosclerosis, Crohn's, Alzheimer's and diabetes. Numerous cytokines play a significant role in this process, though tumor necrosis factor (TNF) and various interleukins are thought to be among the most important regulators. These proinflammatory cytokines promote the above-described diseases by inducing endothelial cell dysfunction. In this brief commentary we will discuss some of the latest advances and discoveries in the treatment of these inflammatory diseases, making use of alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonists.

Original languageEnglish (US)
Pages (from-to)413-416
Number of pages4
JournalPharmaceutical Research
Volume28
Issue number2
DOIs
StatePublished - Feb 1 2011

Fingerprint

alpha7 Nicotinic Acetylcholine Receptor
Cholinergic Agonists
Cytokines
Macrophages
Interleukins
Endothelial cells
Pathogens
Medical problems
Blood Vessels
Veins
Atherosclerosis
Endothelial Cells
Arteries
Tumor Necrosis Factor-alpha

Keywords

  • Jak/STAT pathway
  • alpha7 nicotinic acetylcholine receptor agonists
  • cholinergic anti-inflammatory pathway
  • inflammation

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry
  • Pharmacology (medical)

Cite this

Application of alpha7 nicotinic acetylcholine receptor agonists in inflammatory diseases : An overview. / Marrero, Mario B; Bencherif, Merouane; Lippiello, Patrick M.; Lucas, Rudolf.

In: Pharmaceutical Research, Vol. 28, No. 2, 01.02.2011, p. 413-416.

Research output: Contribution to journalComment/debate

Marrero, Mario B ; Bencherif, Merouane ; Lippiello, Patrick M. ; Lucas, Rudolf. / Application of alpha7 nicotinic acetylcholine receptor agonists in inflammatory diseases : An overview. In: Pharmaceutical Research. 2011 ; Vol. 28, No. 2. pp. 413-416.
@article{f3f1ee0e151e4f5f9aee2a769bcedf90,
title = "Application of alpha7 nicotinic acetylcholine receptor agonists in inflammatory diseases: An overview",
abstract = "Inflammatory disorders are characterized by the influx of immune cells into the vascular wall of veins and/or arteries in response to stimuli such as oxidized-LDL and various pathogens. These factors stimulate the local production of pro-inflammatory cytokines by macrophages and other cells that promote various inflammatory diseases such as atherosclerosis, Crohn's, Alzheimer's and diabetes. Numerous cytokines play a significant role in this process, though tumor necrosis factor (TNF) and various interleukins are thought to be among the most important regulators. These proinflammatory cytokines promote the above-described diseases by inducing endothelial cell dysfunction. In this brief commentary we will discuss some of the latest advances and discoveries in the treatment of these inflammatory diseases, making use of alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonists.",
keywords = "Jak/STAT pathway, alpha7 nicotinic acetylcholine receptor agonists, cholinergic anti-inflammatory pathway, inflammation",
author = "Marrero, {Mario B} and Merouane Bencherif and Lippiello, {Patrick M.} and Rudolf Lucas",
year = "2011",
month = "2",
day = "1",
doi = "10.1007/s11095-010-0283-7",
language = "English (US)",
volume = "28",
pages = "413--416",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Application of alpha7 nicotinic acetylcholine receptor agonists in inflammatory diseases

T2 - An overview

AU - Marrero, Mario B

AU - Bencherif, Merouane

AU - Lippiello, Patrick M.

AU - Lucas, Rudolf

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Inflammatory disorders are characterized by the influx of immune cells into the vascular wall of veins and/or arteries in response to stimuli such as oxidized-LDL and various pathogens. These factors stimulate the local production of pro-inflammatory cytokines by macrophages and other cells that promote various inflammatory diseases such as atherosclerosis, Crohn's, Alzheimer's and diabetes. Numerous cytokines play a significant role in this process, though tumor necrosis factor (TNF) and various interleukins are thought to be among the most important regulators. These proinflammatory cytokines promote the above-described diseases by inducing endothelial cell dysfunction. In this brief commentary we will discuss some of the latest advances and discoveries in the treatment of these inflammatory diseases, making use of alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonists.

AB - Inflammatory disorders are characterized by the influx of immune cells into the vascular wall of veins and/or arteries in response to stimuli such as oxidized-LDL and various pathogens. These factors stimulate the local production of pro-inflammatory cytokines by macrophages and other cells that promote various inflammatory diseases such as atherosclerosis, Crohn's, Alzheimer's and diabetes. Numerous cytokines play a significant role in this process, though tumor necrosis factor (TNF) and various interleukins are thought to be among the most important regulators. These proinflammatory cytokines promote the above-described diseases by inducing endothelial cell dysfunction. In this brief commentary we will discuss some of the latest advances and discoveries in the treatment of these inflammatory diseases, making use of alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonists.

KW - Jak/STAT pathway

KW - alpha7 nicotinic acetylcholine receptor agonists

KW - cholinergic anti-inflammatory pathway

KW - inflammation

UR - http://www.scopus.com/inward/record.url?scp=79952487267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952487267&partnerID=8YFLogxK

U2 - 10.1007/s11095-010-0283-7

DO - 10.1007/s11095-010-0283-7

M3 - Comment/debate

VL - 28

SP - 413

EP - 416

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 2

ER -